#February 2017, #Sector Focus/Pharma

Kiran Mazumdar-Shaw is a consistent presence on definitive global lists as one of the world’s most powerful women. As the Chairman and Managing Director of Biocon Limited, she is a trendsetter in the field of biotechnology in India. Here she takes time out for ‘India Global Business’ to give us an insight into her entrepreneurial drive and India’s own biotech journey.

#February 2017, #Sector Focus/Pharma

The Indian pharmaceutical industry is holding on to a sliver of hope that it could become the supplier of choice for the US market.

Indian IT sector CEOs aren’t the only ones weighing every word uttered by US President Donald Trump for nuances and burning the midnight oil wondering how to maintain their lead in their largest market.

#2016, #Yearend 2016, #World View

India-Russia ties have been rooted in history but 2016 marked a shift in gears to give the relationship a solid 21st century dimension.

President Vladimir Putin’s visit to India in October marked a boost for the Make in India programme with the signing of a slew of deals for the co-production of military helicopters. India also signed up to the purchase of Russian missiles and frigates.

#India-UK, #2016, #October 2016

Beats Mylan, Novartis, Torrent, Aurobindo to the post. Promoter says hungry for more

Almost inarguably, October 5th 2016, a Wednesday was the biggest day in the life of 53 year old Binish Hasmukh Chudgar, the highly low profile vice chairman of Ahmedabad based Intas Pharmaceuticals. That day in central London, Intas snapped up Israeli generic drug maker Teva’s assets in UK and Ireland—Actavis UK Ltd and Actavis Ireland Ltd—in a record $ 764 million deal (Rs 5083 crore) out muscling bigger global rivals like Mylan and Novartis or domestic competition like Aurobindo pharma and Torrent Pharmaceuticals in a bidding process that lasted over 6 months.